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Background: In this study, we investigated the efficacy of continuous epidermal growth factor re-
ceptor (EGFR) tyrosine kinase inhibitors (TKIs) administration in lung adenocarcinoma patients
harboring favorable mutations regarding the progressive disease (PD) status with appearance of
indolent new lesions.
Methods: From June 2010 to October 2012, 102 patients with lung adenocarcinoma, harboring
favorable EGFR mutations and treated with EGFR-TKI were analyzed. Definite new lesions were
detected during EGFR-TKI therapy, even though the primary target tumors were controlled.
Results: Of the 102 patients, 57 continued and 45 discontinued EGFR-TKI therapy. The median overall
survival was 529 days for the discontinuation group and 791 days for the continuation group (p ¼
0.0197). Median survival time after the discontinuation of EGFR-TKI was 181 days and 115 days in the
discontinuation and continuation groups, respectively (p ¼ 0.1776), whereas median survival time
after the appearance of indolent new lesions was 204 days and 262 days, respectively (p ¼ 0.0237).
Conclusion: Continuous EGFR-TKI administration in favorable EGFR-mutative lung adenocarcinoma
patients with controlled primary tumors did not hinder the survival benefit, despite the appearance
of new lesions.acic Medicine, Chang Gung Memorial Hospital at Linkou, 5, Fusing St., Gueishan, Taoyuan
x: þ886 3 3287787.
Y. Liu).
g Gung University.
ublishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
s/by-nc-nd/4.0/).
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Scientific background of the subject
Some advance lung adenocarcinoma patients, harboring
favorable epidermal growth factor receptor mutation,
who were receiving epidermal growth factor receptor-
tyrosine kinase inhibitor, were detected with small
new lesions in the follow-up images, which defined
progressive disease by RECIST criteria. However, these
patients had controlled primary target lesions with sta-
ble clinical condition.
What this study adds to the field
For advance lung adenocarcinoma patients, harboring
favorable epidermal growth factor receptor mutation,
even the appearance of small new lesions while
receiving EGFR-TKI. Continuous EGFR-TKI administra-
tion did not hinder the overall survival and survival time
after the occurrence of new lesions in patients with
controlled primary target lesions.Lung cancer is a leading cause of cancer-related deaths
in both male and female patients worldwide [1]. Nonsmall
cell lung cancer (NSCLC) accounts for approximately 85% of
primary lung cancers and approximately 40% are adeno-
carcinoma [2,3]. The prognosis of the most nonresectable
lung cancers (approximately 80% of NSCLCs) is poor, with a
mean survival of 8e14 months [4]. Anti-epidermal growth
factor receptor (EGFR) agents have been developed as a
treatment for NSCLC and as an alternative to conventional
chemotherapy [5e8]. A subset of patients harboring favor-
able EGFR mutations, such as an exon 19 deletion and L858R,
benefit from EGFR targeted therapy [9,10]. However, most
patients eventually develop the progressive disease (PD)
because of acquired resistance, which might be related to a
second-site EGFR mutation, MET amplification, or other
factors [11].
Previous reports have only described the progression of
local lesions without the representation of systemic resis-
tance; therefore, the clinical definition of acquired resistance
for NSCLC is unclear [12e16]. Our preliminary data showed
that lung adenocarcinoma patients treated with EGFR-
tyrosine kinase inhibitors (EGFR-TKIs) and who had
progression-free survival (PFS) of more than 6 months,
developed new lesions, but remained clinically stable when
EGFR-TKI was continued [17]. However, these patients were
selected based only on the clinical efficacy of EGFR-TKI
treatment with more than 6 months of PFS and they did not
undergo analysis of the EGFR mutation because gene analysis
was not performed routinely in clinical practice in our insti-
tute before 2009. New lesions are considered when a lesion is
identified through follow-up imaging of an anatomic location
without lesions at baseline [18]. The appearance of one or
more new lesions is defined as PD by the Response Evaluation
Criteria in Solid Tumors (RECIST) guideline (version 1.0, pub-
lished in 2000) [19].However, according to the revised RECIST 1.1 guidelines
(2009), the first appearance of new lesions might not defini-
tively indicate PD. If new lesions cannot be identified
initially, treatment can be continued until the next sched-
uled assessment. Nonetheless, follow-up imaging that con-
firms the development of new lesions should also confirm PD
[18], after which therapeutic agents should be altered.
However, acute deterioration of disease after EGFR-TKI
withdrawal has been reported in EGFR-mutant lung cancer
patients with acquired resistance [14]. Furthermore, in clin-
ical practice, some patients with a first appearance of new
malignant lesions and PD have been observed to regain dis-
ease stability when the original EGFR-TKI treatment is
continued [17].
The present study was intended to determine whether the
survival of a subset of patients with EGFR mutative lung
adenocarcinoma, with controlled target lesions, and new
malignant lesions could be affected by discontinuing EGFR-
TKI based on the appearance of new lesions, which are
defined by RECIST, a PD status.Methods
Study population
From June 2010 to October 2012, 486 patients diagnosed with
stage IIIB or IV primary lung adenocarcinoma were tested for
EGFR mutation status and were screened. All the patients
were enrolled in the NHI program of Taiwan and received
comprehensive and updated therapy for NSCLC. The patients
were evaluated to determine the stage of the disease before
the start of treatment, at regular intervals, and for disease
progression or relapse. The disease stage was determined
according to a complete medical history; physical examina-
tion; imaging survey, including chest X-ray (CXR) and
computed tomography (CT) of the chest and abdomen; and
additional staging procedures such as magnetic resonance
imaging (MRI) of the head, bone scintigraphy, and fluo-
rodeoxyglucose positron-emission tomography (FDG-PET).
Tumor response was assessed during therapy, based on
RECIST Version 1.0 or 1.1, depending on the respective year.
Patient's lung cancer-related symptoms such as dyspnea,
cough, hemoptysis, chest pain, and metastatic-lesion-related
symptoms were recorded at each clinical visit or hospitaliza-
tion. Clinical information was prospectively recorded
following the Chang Gung Memorial Hospital (CGMH) lung
cancer protocol and retrieved from the Cancer Registry Sys-
tem of the Cancer Center of CGMH.
Patient selection
The inclusion criteria were: (1) Patients with EGFR mutations
that were sensitive to EGFR-TKI; (2) patients who had received
EGFR-TKI therapy; (3) patients who were receiving EGFR-TKI
therapy with controlled target primary lung tumors and pre-
existing metastatic tumors; (4) appearance of small new le-
sions in the follow-up images during EGFR-TKI therapy,
defined as PD by RECIST; (5) patients who were asymptomatic
or exhibited stable preexisting symptoms or mild symptoms
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status. The exclusion criteria were: (1) Patients with wild-type
EGFR or amutation that was resistant to EGFR-TKI; (2) patients
who had never received EGFR-TKI; (3) patients who were
receiving EGFR-TKI treatment without PD status; (4) patients
who had PD related to primary lung tumors or preexisting
metastatic tumors; (5) patients who exhibited deterioration of
preexisting symptoms or new symptoms that in turn deteri-
orated the general condition or performance status. The way
of patient selection was summarized in Fig. 1.
Data for 102 patients with a mean age of 61.7 ± 13.0 years,
favorable mutations of EGFR and exhibiting new lesions with
controlled primary target lung, and preexisting metastatic
lesions meeting the enrolled criteria were retrieved from the
prospective recording and registry system. The retrospec-
tively analyzed data included demographics (age and sex),
initial lung cancer stage, performance status, smoking status,
line of EGFR-TKI treatment and duration, PFS, overall survival
(OS), survival before administration and after the discontin-
uation of EGFR-TKI, survival after the occurrence of new le-
sions (RECIST-defined PD), and site of the new lesions. The
EGFR mutations were detected using direct sequencing and
ARMS-Scorpion methods, which have been firmly established
in the Central Molecular Lab of the Department of Pathology
at CGMH, a College of American Pathologists-accredited
laboratory.Treatment after the appearance of small new lesions
All the patients received considerably close follow-up with
CXR every 1e4weeks and CT every 1e2months for pulmonary
tumors or other new lesions and MRI for bone or brain lesions
to evaluate the treatment response and tumor progression.
Pulmonary oncologists integrated information from theFig. 1 e Patient selection flow chart.radiographic images and the speed of progression in the in-
terval between the imaging studies to determine optimal
therapy after re-staging. EGFR-TKI in the continuation group
was used until PD of the primary target lung lesions, persis-
tent progression of new lesions, or deterioration of related
symptoms. In the continuation group, EGFR-TKI was
continued for more than 1month after the appearance of new
lesions, and clinicians continued EGFR-TKI based on the
principle of intent to treat, the patients' requests, and
consideration of the benefits and tolerance of switching to
chemotherapy. For the discontinuation group patients, EGFR-
TKI was discontinued within 1-month of the appearance of
new lesions with or without switching to another treatment.
Statistical analysis
Data are presented as means ± standard deviation except
where otherwise mentioned. Because the data did not
approximate a Gaussian distribution, a nonparametric sta-
tistical analysis, theManneWhitney U-test was performed for
unpaired data to assess the significance of the difference be-
tween the two groups. Frequency distributions between the
two groups were tested using the Chi-square or Fisher's exact
probability tests. Survival rates were calculated using the
KaplaneMeier method, and a comparison of survival curves
was based on the log rank test and hazard ratio (HR) was
produced via Cox proportional hazards model. All the tests
were two-sided and p < 0.05 was considered as statistically
significant. GraphPad Prism (Version 5.0; GraphPad Software,
San Diego, CA, USA) was used for all the statistical analyses.Results
A representative patient with continued epidermal growth
factor receptor-tyrosine kinase inhibitors after the
appearance of indolent new lesions
A representative patient with metastatic lung adenocarci-
noma was treated with cisplatin and paclitaxel for 6 cycles as
first-line therapy. After 185 days of disease control, the tumor
progressed [Fig. 2A]. An EGFR mutation test was conducted
and a mutation of exon 19 deletion was detected. Therefore,
gefitinib was administrated as the subsequent second-line
treatment. After the administration of EGFR-TKI for 660
days, new brain lesionswere detected in a follow-up brainMRI
that was performed based on the complaints of mild dizzi-
ness. Because this patient had no other newly developing
neural symptoms and the primary lung tumor was being
controlled by EGFR-TKI treatment, the treatment was
continued without switching or additional therapy such as
brain irradiation. These brain lesions exhibited a stable dis-
ease status without progression, with the continuation of
EGFR-TKI treatment. New lung lesions after 793 days of EGFR-
TKI were detected in regular follow-up chest CT with
controlled targeted lesions, but without alterations in clinical
manifestations. The new lung nodules were stationary after
the continuation of EGFR-TKI to 879 days [Fig. 2BeF]. Gefitinib
was discontinued at day 935 because additional new lung le-
sions were appeared and the primary target lung tumor was
Fig. 2 e A patient with metastatic lung adenocarcinoma received 6 cycles of cisplatin plus paclitaxel as first-line chemotherapy.
The primary lung tumor then enlarged with disease progression. The epidermal growth factor receptor mutation test revealed
an exon 19 deletion mutation, and the patient then received gefitinib as subsequent second-line therapy. (A) Primary right
upper lobe (RUL) lung tumor before second-line gefitinib treatment was administered. (B) Regression of the targeted RUL lung
tumor after 90 days of gefitinib treatment. (C) First appearance of new brain lesions after 660 days of gefitinib treatment. (D)
Stationary brain lesions after 788 days of gefitinib treatment. (E) First appearance of new, minute, nodular lung lesions after 793
days of gefitinib treatment. (F) More new, minute, and stationary nodular lung lesions after 879 days of gefitinib treatment.
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switched to chemotherapy with pemetrexed, which was
administered for 12 cycles as third-line therapy. Survival time
after discontinuing EGFR-TKI was 336 days. In summary, this
patient regained a stable clinical condition after continuing
EGFR-TKI, even though new nodular lung and brain lesions
were waxed and waned [Fig. 2].
Characteristics of patients with new lesions receiving
epidermal growth factor receptor-tyrosine kinase inhibitors
treatment
A total of 102 patients with advanced and metastatic lung
adenocarcinoma, with sensitive mutations, and receiving
EGFR-TKI treatment were analyzed [Table 1]. Eight patients
(7.8%) were stage IIIB and 94 (92.2%) were stage IV. Forty-five
patients discontinued EGFR-TKI treatment and receivedfurther management, whereas 57 patients continued EGFR-
TKI treatment for more than 1 month after the appearance
of new indolent lesions. Thirty-seven (75%) patients in the
discontinuation group received EGFR-TKI treatment as first-
line therapy, whereas 34 (59.6%) in the continuation group.
Forty-three patients received gefitinib initially in the contin-
uation group, among who continued gefitinib at the first
appearance of new lesions and 2 switched to erlotinib for
personal insurance reasons. The other 14 patients in the
continuation group, who received erlotinib initially, continued
the same targeted therapy. No significant difference was
observed in the performance status between the continuation
and discontinuation groups, after the occurrence of new
lesions.
Among the 57 patients with continuous EGFR-TKI therapy,
17 had new lesions in the lung and 40 had extra-pulmonary
new lesions. For the 45 patients in the discontinuation
Table 1 e Patient characteristics.
Characteristics Total EGFR-TKI p
Discontinued Continued
Number of patients 102 45 57
Age (year) 61.7 ± 13.0 63.2 ± 11.7 60.5 ± 14.0 0.2431
Gender (male/female) 46/56 19/26 27/30 0.6040
Smoking (never/former þ current) 76/26 34/11 42/15 0.4148
Stage (IIIB/IV) 8/94 3/42 5/52 0.4965
PS (0e1/2e4) at diagnosis 79/23 33/12 46/11 0.2586
PS (0e1/2e4) after new lesion 59/43 26/19 33/24 0.5748
EGFR mutation
Exon 21 L858R 46 22 24 0.4942
Exon 19 deletion 50 21 29 0.6947
Other sensitive but rare mutationsa 6 2 4 0.6917
Duration of EGFR-TKI treatment (days) 427 ± 236 358 ± 186 500 ± 264 0.0076
Duration of EGFR-TKI treatment after definite new lesions (days) 88 ± 110 14 ± 6 167 ± 112 0.0001
Progression-free survival with EGFR-TKI (median days) 263 279 254 0.6437
Overall survival (median days) 650 529 791 0.0197
Initial EGFR-TKI (gefitinib/erlotinib) 82/20 39/6 43/14 0.1210
Lines of EGFR-TKI 0.0527b
1st 71 37 34 0.0173
2nd 25 7 18 0.0687
3rd 6 1 5 0.2246
Overall survival of first-line EGFR-TKI patients (median days) 628 (n ¼ 71) 518 (n ¼ 37) 657 (n ¼ 34) 0.0532
Overall survival of non-first-line EGFR-TKI patients (median days) 806 (n ¼ 31) 865 (n ¼ 8) 806 (n ¼ 23) 0.9761
Time prior to EGFR-TKI use (median days) 25 19 32 0.2242
Survival time after the discontinuation of EGFR-TKI (median days) 163 181 115 0.1776
Survival time after definite new lesions (median days) 248 204 262 0.0237
Location of new lesions
Lung lesions 23 6 17 0.0582
Nonlung lesions 79 39 40 0.0582
Number of organs with metastasis (mean, 95% CI) 1.67 ± 0.95 1.62 ± 0.91 1.70 ± 0.98 0.5695
Overall survival of lung new lesion patients (median days) 544 (n ¼ 23) 732 (n ¼ 6) 544 (n ¼ 17) 0.7581
Overall survival of nonlung new lesion patients (median days) 644 (n ¼ 79) 528 (n ¼ 39) 748 (n ¼ 40) 0.0080
Abbreviations: SD: Standard deviation; PS: Performance status; EGFR: Epidermal growth factor receptor; EGFR-TKI: Epidermal growth factor
receptor-tyrosine kinase inhibitors; CI: Confidence interval.
a Other sensitive mutations: Exon 18 G719A (2), exon 19 E746G (1) exon 19 L747P (1), exon 20 S768I (1), exon 20 R776H (1), exon 21 L861Q (2). Two
patients had double mutations and both were in the discontinuation group.
b Multiple contingency table analyses.
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extra-pulmonary new lesions. The locations and characteris-
tics of the new lesions are summarized in Supplementary
Table 1.
Thirty patients were noted to have new lesion-related
symptoms, which are summarized in Supplementary Table
2. No significant difference in these symptoms was observed
among the groups. The median OS in the patients with new
lesion-related symptomswas 650 days for the discontinuation
group and 791 for the continuation group (HR: 1.311, 95%
confidence interval [CI]: 0.5508e3.120, p ¼ 0.5407)
[Supplementary Table 2].
Progression-free survival and overall survival
The median time from diagnosis to the 1st time use of EGFR-
TKI therapy was 19 days and 32 days for the discontinuation
and continuation groups, respectively (HR: 1.294, 95% CI:
0.8540e1.294, p ¼ 0.2242) [Fig. 3A]. PFS with EGFR-TKI therapy
was 279 days for the discontinuation group and 254 days for
the continuation group (HR: 1.028, 95% CI: 0.6404e1.65;
p¼ 0.6437) [Fig. 3B]. Themedian OSwas 529 days and 791 daysfor the discontinuation and continuation groups, respectively
(HR: 1.839, 95% CI: 1.102e3.070, p ¼ 0.0197) [Fig. 3C]. The me-
dian survival time after the discontinuation of EGFR-TKI was
181 days for the discontinuation group and 115 days for the
continuation group (HR: 0.7106, 95% CI: 0.4332e1.166,
p ¼ 0.1776) [Fig. 3D]. Survival time after the appearance of
definite new lesions (RECIST-defined PD) was 204 days and 262
days for the discontinuation and continuation groups,
respectively (HR: 1.516, 95% CI: 0.9201e2.498, p ¼ 0.0237)
[Fig. 3E]. The PFS of first subsequent new treatment after
EGFR-TKI was 125 and 92 days for the discontinuation and
continuation groups, respectively (HR: 1.009, 95% CI:
0.6192e1.643, p ¼ 0.9724) [Fig. 3F]. Particular subsets of pa-
tients in both groupswere also analyzed [Table 1]. For patients
receiving EGFR-TKI as first-line therapy, the median OS was
518 days for the discontinuation group and 657 days for
continuation group (HR: 0.5455, 95% CI: 0.2952e1.0084,
p ¼ 0.0532). For patients with lung new lesions, the median OS
was 732 days for discontinuation group and 544 days for the
continuation group (HR: 1.204, 95% CI: 0.3692e3.927,
p¼ 0.7581). For patientswith nonlung new lesions, themedian
OS was 528 days for the discontinuation group and 748 days
Fig. 3 e Survival proportion traced using the KaplaneMeier method. (A) Median time to the use of epidermal growth factor
receptor-tyrosine kinase inhibitors between the discontinuation and continuation groups was 19 versus 32 days (hazard ratio:
1.294, 95% confidence interval: 0.8540e1.294; p ¼ 0.2242). (B) Median progression-free survival with epidermal growth factor
receptor-tyrosine kinase inhibitors for the discontinuation and continuation groups: 279 and 254 days, respectively (hazard ratio:
1.028, 95% confidence interval: 0.6404e1.65; p ¼ 0.6437). (C) Median OS for the discontinuation and continuation groups was 529
and 791days, respectively (hazard ratio: 1.839, 95%confidence interval: 1.102e3.070; p¼ 0.0197). (D)Median survival timeafter the
discontinuation of epidermal growth factor receptor-tyrosine kinase inhibitors for the discontinuation and continuation groups
was 181 and 115 days, respectively (hazard ratio: 0.7106, 95% confidence interval: 0.4332e1.166; p ¼ 0.1776). (E) Median survival
time after the appearance of new lesions for the discontinuation and continuation groups was 204 and 262 days, respectively
(hazard ratio: 1.516, 95% confidence interval: 0.9201e2.498, p ¼ 0.0237). (F) The median progression-free survival of first-
subsequent new treatment after epidermal growth factor receptor-tyrosine kinase inhibitors was 125 and 92 days for the
discontinuation and continuation groups, respectively (hazard ratio: 1.009, 95% confidence interval: 0.6192e1.643, p ¼ 0.9724).
b i om e d i c a l j o u r n a l 3 9 ( 2 0 1 6 ) 1 2 1e1 2 9126for the continuation group (HR: 0.4537, 95% CI: 0.2528e0.8137,
p ¼ 0.0080).
Further management of new lesions and subsequent
therapy after epidermal growth factor receptor-tyrosine
kinase inhibitors treatment
The management at the appearance of new lesions and sub-
sequent treatment are summarized in Table 2. After the
appearance of the new lesions, 11 patients received additional
radiation therapy and 46 continued with EGFR-TKI alone in
the continuation group. Among the 45 patients, who dis-
continued EGFR-TKI therapy, treatment was switched from
EGFR-TKI to chemotherapy alone in 25 patients, 16 received
radiation therapy, 12 underwent chemotherapy accompanied
with radiation therapy, and 2 received radiation therapy alone
for the treatment of brain and bone lesions [Table 2].
Among the 57 patients in the EGFR-TKI continuation group,
38 received subsequent chemotherapy after EGFR-TKI wasdiscontinued. Twenty-three patients in the continuation
group were re-treated with EGFR-TKI after chemotherapy and
22 were re-treated with EGFR-TKI in the discontinuation
group. Twenty-four (23.5%) patients received best supportive
care after EGFR-TKI [Table 2].Discussion
In clinical practice, indolent new lesions with controlled pri-
mary target lung lesions are observed in the follow-up images
of patients who have lung adenocarcinoma harboring sensi-
tive EGFR mutations and are receiving EGFR-TKI treatment.
Some patients have been observed to have uncommonly long
survival time and clinical stability when they received
continuing EGFR-TKI treatment, even after the first appear-
ance of new lesions. In the present study, further analysis of
the patients with lung adenocarcinoma harboring sensitive
EGFR mutations and receiving EGFR-TKI therapy showed that
Table 2 e Management after the appearance of new
lesions and subsequent therapy after EGFR-TKI.
Management of new
lesions
EGFR-TKI p
Discontinued Continued
Number of patients 45 57
Radiation therapy 16 11 0.0744
Radiation therapy to brain 6 5 0.6794
Radiation therapy to bone 10 6 0.6974
EGFR-TKI alone 0 46 <0.0001
Systemic chemotherapy
alone
25 0 <0.0001
EGFR-TKI combined
radiation therapy
0 11 0.0021
Chemotherapy combined
with radiation therapy
12 0 <0.0001
Subsequent therapy after EGFR-TKI
Radiation therapy 16 12 0.1032
Chemotherapy 37 38 0.0770
Platinum-base doublet
chemotherapy
21 23 0.7403
1 subsequent
chemotherapy
22 20 0.5515
2 subsequent
chemotherapies
15 18 0.5515
Re-treated with EGFR-TKI 20 23 0.6776
BSC 10 14 0.7821
Median PFS of subsequent new treatment
Median PFS (days) 125 92 0.9724
Abbreviations: EGFR-TKI: Epidermal growth factor receptor-
tyrosine kinase inhibitors; PFS: Progression-free survival; BSC:
Best supportive care.
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patients receiving continued EGFR-TKI therapy were not
inferior to those of the discontinuation group. These results
suggested a possible dynamic balance between tumor growth
and cell death on the continuation of reversible EGFR-TKI
therapy, as indicated by the central attenuated nodules and
waxing and waning tumor size in the patients. Differences in
the histological growth patterns andmolecular characteristics
of lung adenocarcinoma may influence the clinical outcome
[20]. Some tumor cells can remain sensitive to EGFR-TKI after
the occurrence of new lesions, which can complicate the
decision-making, regarding the selection of therapeutic
agents when new lesions or PD occurs [18].
Most patients with EGFR-mutant lung adenocarcinoma,
receiving EGFR-TKI treatment, develop PD after a median
time of 10e16 months [21]. Acquired resistance to EGFR-TKI
may involve a reversible “drug-tolerant” state, the mecha-
nism of which must be established; furthermore, the con-
tributions of specific resistance-conferring mutational and
nonmutational mechanisms and the role of tumor cell sub-
populations to drug resistance remain unclear [22]. A previ-
ous study reported that in NSCLC patients, who were initially
responded, but later developed acquired resistance to EGFR-
TKI, gefitinib, or erlotinib, discontinuing EGFR-TKI, resulted
in symptomatic progression and increased tumor size [13].
Symptoms were improved and tumor size was decreased
after restarting EGFR-TKI, suggesting that a proportion of
cells in a resistant tumor cell population remain sensitive to
EGFR and that EGFR-TKI may be beneficial even after theRECIST-defined PD [13]. A recent study also showed that
EGFR-TKI re-treatment can be effective after failure of initial
gefitinib treatment [16], and some EGFR-mutant lung cancer
patients with PD experienced disease flare after discontinu-
ing EGFR-TKI and after initially benefiting from erlotinib or
gefitinib [14].
Re-treatment with erlotinib can be helpful even for NSCLC
patients who initially get benefit from previous EGFR-TKI
treatment and progress after standard cytotoxic chemo-
therapy [15]. Another recent study showed the possible benefit
of continuous EGFR-TKI administration following radio-
therapy after PD in isolated CNS metastasis [12]. Yang et al.
[23] reported that the continuation of EGFR-TKI yielded longer
OS in a certain subgroup of NSCLC patients who had already
failed EGFR-TKI. For patients who hadmild symptoms or were
asymptomatic with a slow increment of tumor burden,
continuing EGFR-TKI alone was recommended. In the present
study, the patients in the EGFR-TKI continuation group had
significantly longer survival rate after the appearance of new
lesions than had those in the discontinuation group. More-
over, patients who received continuous EGFR-TKI after the
appearance of new lesions had the same opportunity to
receive subsequent treatment after discontinuing EGFR-TKI as
those in the discontinuation group did. In addition, no sig-
nificant difference was observed in the PFS of subsequent
post-EGFR-TKI treatment between the two groups. Although
the survival after discontinuing EGFR-TKI seemed longer in
the discontinuation group than in the continuation group, our
data suggested that continuing EGFR-TKI after the appearance
of new lesions can maintain clinical stability for a period and
dose not hinder OS. Continuous EGFR-TKI treatment can
remain as an effective option for therapy when new lesions
occur. Additional, prospectively designed studies are critical
for determining the appropriate management of NSCLC pa-
tients with EGFR-sensitive mutations receiving TKI therapy
and with the appearance of local or indolent disease
progression.
Response to additional local therapy in patients receiving
prolonged EGFR-TKI therapy after the occurrence of new le-
sions might also suggest a favorable outcome, which is
consistent with previous reports [12,24]. Local intervention
such as radiation therapy for new lesions has been recom-
mended by the aforementioned studies. The local interven-
tion can be withheld and administered electively, if patients
exhibit clinical stability after EGFR-TKI therapy, asymptom-
atic extra-pulmonary lesions, or onlymild symptoms that can
be controlled and do not deteriorate the patients' general
clinical condition. Several studies have indicated the safety of
systemic chemotherapy and EGFR-TKI without radiation
therapy for NSCLC patients with brain metastasis [25e27].
Accordingly, some patients in this study did not receive extra-
pulmonary local therapy based on the clinical stability of the
patients and the consideration of adverse effects from
therapy.
According to the Iressa Pan-Asia Study and other similar
reports [6,8,28], the efficacy of EGFR-TKI regarding OS is
similar to first- and second-line use. Our survival analysis
showed that patients who received EGFR-TKI treatment
continuously after the first appearance of definite new lesions
had a significantly longer median OS. The PFS of EGFR-TKI did
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discontinuing EGFR-TKI. Nevertheless, survival time was
longer for patients with continuous EGFR-TKI after the
appearance of new lesions compared with that of the
discontinuation group. Hence, the data in this study suggest
the possible survival benefits of the individualized extension
of EGFR-TKI therapy for patients with lung adenocarcinoma
harboring sensitive EGFRmutations and controlled target lung
tumors, despite the appearance of new lesions.
A review of the characteristics of new lesions in patients
with continuous EGFR-TKI therapy revealed that a smaller
size and number of lesions and nodular patterns with central
low-attenuation in radiographic images suggesting tumor
necrosis might predict possible benefits of continuous EGFR-
TKI. Therefore, the prolongation of EGFR-TKI therapy can be
considered as a factor contributing to the survival benefit in
the present study. Patients in the continuation group received
EGFR-TKI until progression of the primary target lung lesions
or the appearance of new lesions with overall disease deteri-
oration. Definite new lesions are typically considered as PD
and a change in regimen is always suggested in clinical
practice. However, both previous reports and the present
study indicate that continuous EGFR-TKI might still be effec-
tive for a particular subset of patients although the charac-
teristics of such patients and the mechanism require further
investigation.
If FDG-PET is not performed at baseline, the interpretation
of new lesions depends on a comparison among the follow-up
CT images [18]. Thus, the first appearance of new lesions
might not definitively indicate PD. FDG-PET and low-dose
high-resolution CT can help evaluate tumor volume and the
increase in the speed of volume. In the present study, some
new lesions were remained stable or regained responsiveness
to continuous EGFR-TKI, and OS was not hindered. This sug-
gests that for patients receiving EGFR-TKI therapy and with
controlled primary target lesions, the policy of changing
medication on the appearance of definite new lesions war-
rants further evaluation. Moreover, a practical adjunct test to
evaluate the systemic acquired resistance and tumor pro-
gression more thoroughly than by using the anatomic defini-
tion should be developed.
This study had several limitations. Because Taiwan's NHI
program has covered the first and second lines of TKI treat-
ment for only a few years, the number of patients with a
completed therapeutic course and adequate follow-up time
retrieved from the Cancer Registry System of our hospital was
limited. Therefore, only a small number of patients were
enrolled, which made subset analysis difficult. Although
conditional or subset survival analysis can be used in the
evaluation of difference for a heterogeneous group in a clinical
study [2], the small number of patients in this study, hindered
further survival risk analysis based on the sensitive mutation
subtypes or the patterns of imaging studies for newly devel-
oped lesions, and significant predictors for continuing or dis-
continuing EGFR-TKIwithout bias or with a clear pathogenetic
basis could not be determined. In our study, differences were
observed in some baseline characteristics among the groups
such as the proportion of first-line therapy with EGFR-TKI and
pulmonary or nonpulmonary new lesions. However, the me-
dian OS analyzed for these subgroups had a similar trend asthat of overall patients. In addition, because this was a
retrospective study, the treatments were determined accord-
ing to the clinical decisions of the physicians, caring for the
patients under the principle of intent to treat. The patients
were not randomized into each subsequent treatment group
and selection bias might have existed, which might have
influenced the PFS and OS. Although all of the patients in the
present study were evaluated for lesions by using chest ra-
diographs, CT, MRI, bone scintigraphy or PET, according to the
predetermined management protocols set by our cancer
center, the intervals among the evaluations were not as uni-
form as those in a prospective trial. A prospective studywith a
larger patient population is required to validate and apply our
findings in clinical practice.Conclusion
Continuous EGFR-TKI did not hinder OS and survival time
after the occurrence of new lesions in patients with lung
adenocarcinoma harboring sensitive mutations of EGFR and
with controlled primary target lung lesions. A prospective
study with a larger number of patients is warranted to char-
acterize the predictive factors for the benefit of continuous
TKI and to establish a therapeutic strategy for patients ful-
filling these criteria.Ethics statement
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